Experts highlight ten common requests received in their Gastroenterology advice and guidance service and explain how these ...

The prospectus describes RBD4059, one of Ribo Life's core candidate products, as the world's first and most advanced siRNA ...

Q1 2025 Earnings Call Transcript May 6, 2025 Dynavax Technologies Corporation misses on earnings expectations. Reported EPS is $0.01 EPS, expectations were $0.03. Operator: Good day ladies and ...

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the first quarter of 2025, along with recent ...

BRIUMVI U.S. net revenue of $119.7 million. Raises full year 2025 global net revenue target to approximately $575 million and raises full year BRIUMVI U.S. net ...

Story March 27 - Arbutus Biopharma: Arbutus is stripping back its workforce to just a “core team” needed to oversee mid-stage trials of the biotech's potential functional cure for hepatitis B.

In addition to HBsAg, other viral markers such as hepatitis B core-related antigen (HBcrAg ... after in vitro stimulation with HBV-specific peptides Ex vivo phenotyping of total T cells and ...

Objective Hepatitis B virus (HBV) can integrate into the ... were also observed in the open reading frame preC/Core (ORF C), ORF P, and ORF P region overlapping with ORF S (figure 5A). Intrahepatic ...

Vir Bio (VIR) reveals 24-week post-end-of-treatment data from a mid-stage trial for its Hep B therapy developed with Xencor ...

Discover a recent study presented at EASL 2025 that explored the impact of opt-out testing for blood-borne viruses in ...

An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV) in a mid-stage trial, setting up a phase 3 assessment next year to see if it could offer a ...

DB-1305/BNT325 was generally well tolerated and exhibited “very encouraging and durable antitumor activity in ovarian cancer patients,” said Maria Rubinstein, MD.